King's College London

Funding Information: The authors do not have any conflicts of interest to declare in relation to this guideline. All authors have completed an ICMJE disclosure form. In the last three years, Isabel J Skypala has received funding from ThermoFisher, the Royal College of General Practitioners (RCGP) and TouchIME. Stephen J. Till has received funding from Revolo Biotherapeutics, Astra Zeneca and National Institute of Health Research (NIHR). Mamidipudi Thirumala Krishna has received funding from NIHR, University of Birmingham, Medical Research Council, Global Challenges Research Fund and the Food Standards Agency, Hannah Hunter has received funding from ASIT Biotech. George du Toit has received funding from the Immune Tolerance Network and the National Institute of Allergy and Infectious Diseases. Elizabeth Angier has received funding from the Natasha Allergy Research Foundation, Local Medical Committee and the RCGP. The following authors have no disclosures to declare; David Luyt, Helena Rey Garcia, Kostadin Stoenchev, Funding Information: The writing group would like to acknowledge the huge help and support for this guideline from Dr Maryam Shayeghi, the BSACI Chief Scientific Officer until May 2021 and also her successor Erinn Gallagher. The final version of this document has been shaped by extensive discussions within SOCC, with many members providing valuable feedback. In particular, the writing group would like to acknowledge the support of Pam Ewan, Liz Powell, Helen Fisher, Deb Marriage, Prathap Pillai, Jose Maia Costa, Rita Mirakian, Nasreen Khan, Susana Marinho, Andy Clark, Chris Corrigan and Lavanya Diwakar. Their comments on successive documents were timely and most helpful. The authors would also like to thank Margaret Kelman from Allergy UK, who provided comments on various drafts of the document. These guidelines inform the management of pollen food syndrome. Adherence to these guidelines does not constitute an automatic defence for negligence and conversely, non-adherence is not indicative of negligence. It is anticipated that these guidelines will be reviewed every 5–7 years. There have been no funding sources for this guideline. The commercial companies or institutions BSACI have been in partnership with from 2020 to 2022 include, Sanofi Genzyme, Thermo Fisher Scientific, Novartis, Mylan, Allergy Therapeutics, Diagenics ALK Abello, Takeda, Aimmune Therapeutics, Viatris, Bio Cryst Pharmaceuticals, Indoor Biotechnologies, Captium, Scope, InBio, Reckitt Benckiser, DBV Technologies, Glenmark, Food Standards Agency and Stallergenes. The commercial companies or institutions that Anaphylaxis Campaign have been in partnership for the same period are Aimmune, ALK, Bausch & Lomb, Aston University, DBV, Co-op, Kantar Health, Viatris, Food Standards, Agency, York Health, Eton College, Manchester University. Publisher Copyright: © 2022 John Wiley & Sons Ltd.